The latest data presented at VIVA

VIVA's virtual conference will once again feature our much-anticipated Late-Breaking Clinical Trials sessions. Physicians and researchers from around the world will present groundbreaking research from clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs. A multidisciplinary, international panel of expert physicians, scientists, and regulators will ask questions and shed light on the lasting impact of the research results presented.

Abstract Submissions

A limited number of abstracts will be accepted for presentation. Please read the submission guidelines carefully before submitting your abstract for consideration. Accepted late-breaking clinical trials will be presented on the virtual platform Friday and Saturday, November 6 and 7. Each presentation will be followed by a Q&A with a panel of expert faculty.

Submission Guidelines

The abstract submission deadline is August 27, 2020. Research must be original and may not have been presented prior to the Late-Breaking Clinical Trials sessions at VIVA20. Abstracts must be submitted electronically via the official VIVA abstract submission website.

Abstract submissions should address areas of endovascular medicine and can report the results of basic science investigations as well as clinical or pre-clinical studies.

Abstract submissions must include:

  • Trial name
  • Purpose
  • Materials and methods
  • Results
  • Conclusions

The total abstract length may not exceed 2,500 characters, exclusive of title or figures. The following information must be provided upon submission:

  • Submitter Name
  • Primary Contact name
    • Organization/institution
    • Phone number
    • E-mail address
  • Names of up to three authors
  • Name of who will present the abstract if selected
    • Phone number
    • E-mail address
  • Name of the company or entity providing funding or research support
  • Six-word title for abstract presentation


Submitted abstracts will be reviewed after the August 27 submission deadline. Abstracts will be evaluated and scored based on the following criteria:

  • Interest to field
  • Research methods
  • Quality of data
  • Primary endpoint presented

Notification of acceptance or rejection will be sent the week of September 7, 2020. Subsequent communication will provide specifics about submitting your presentation, the date and time of the presentation, and virtual platform information.

If you have questions please contact Rachel DeLuna via e-mail:


VIVA embargoes information presented in the Late-Breaking Clinical Trials sessions from becoming public until after the commencement of the assigned session as listed in the VIVA20 program or on the official VIVA website. No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented. Presentation times will be provided and listed in VIVA course materials. All times are listed in Pacific Standard Time (PST).

Submit now